(Reuters) – Sanofi has started talks with investment bank Rothschild & Co about plans to spin off and separately list its Consumer Healthcare business, which could be valued at more than $20 billion, reports said. Bloomberg on Wednesday, citing sources familiar with the matter.
This activity, which notably manufactures Doliprane, has attracted initial interest from large private equity companies who are evaluating a potential acquisition, adds Bloomberg.
(Written by Victor Goury-Laffont and Bertrand Boucey)
©2023 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.